Veracyte to Acquire C2i Genomics to Add Whole-Genome MRD Capabilities

Veracyte Acquires Convergent Genomics to Expand Urinary Tumor DNA Bladder Cancer Diagnostics

September 14, 2026

Healthcare Services

Veracyte announced its acquisition of Convergent Genomics to add the UroAmp urinary tumor DNA (utDNA) platform to its cancer diagnostics portfolio. The technology is intended to help guide non-muscle-invasive bladder cancer care by enabling urine-based therapy-response monitoring and post-treatment surveillance.

Charles River Laboratories Acquires Vigene Biosciences

May 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.

CD&R, Merck GHI and McKesson Ventures Recapitalize M2GEN

March 17, 2021

Healthcare Services

Clayton, Dubilier & Rice (CD&R) led a recapitalization of oncology data and informatics company M2GEN, with strategic investments from Merck Global Health Innovation Fund and McKesson Ventures. The transaction — which closed with terms undisclosed — positions CD&R as the largest shareholder and will fund growth of M2GEN's linked clinical and genomic data assets and expanded technology and informatics capabilities.

Veracyte Acquires Decipher Biosciences

February 3, 2021

Biotechnology

Veracyte, Inc. has entered into a definitive agreement to acquire Decipher Biosciences, a commercial-stage precision oncology company focused on urologic cancers, for $600 million in total consideration ($250 million cash and up to $350 million in stock). The acquisition expands Veracyte’s genomic cancer diagnostics menu, adds Decipher’s commercial tests and data assets, and is expected to accelerate revenue growth and global market reach.

OncoCyte Corporation Acquires Insight Genetics

January 10, 2020

Healthcare Services

OncoCyte Corporation agreed to acquire all outstanding capital stock of Insight Genetics, a privately held molecular diagnostics company, for approximately $12 million in cash and stock plus potential contingent payments. The acquisition adds Insight Genetics' IM Score immuno-oncology diagnostic test and a pharma-trial–capable CLIA/CAP lab to OncoCyte's portfolio to expand its capabilities in oncology diagnostics and pharma services.

Veritas Genetics Acquires Curoverse

August 3, 2017

Biotechnology

Veritas Genetics has acquired Boston-based Curoverse, the creator of the Arvados open-source genomic data platform, for an undisclosed amount. The acquisition brings Curoverse’s bioinformatics, data-management and AI/ML capabilities in-house to expand Veritas’s capacity for large-scale genome interpretation and deploy machine learning across millions of genomes.